Absci (ABSI) just outlined the design for its planned global Phase 2 STORYLINE trial of ABS-201 in endometriosis, giving investors fresh detail on patient recruitment, endpoints, and expected timing into 2027.
The ABSI share price has pulled back about 11% in the last day, even after a 16% 30-day share price return and a very strong year-to-date move of 184%. The 3-year total shareholder return of more than 6x signals that sentiment around Absci’s pipeline has already shifted materially over a longer window.
Scan more AI-driven drug discovery plays moving on clinical catalysts with a curated list of 34 healthcare AI stocks that share Absci’s blend of biotech and machine learning focus.
After a 184% year-to-date run and a pullback to US$10.27, Absci now trades roughly 40% below the average analyst target. Does that gap reflect upside left in the story or expectations already stretched?
Most Popular Narrative: 25% Undervalued
Against Absci’s last close at $10.27, the most followed fair value estimate of about $13.78 points to a sizeable valuation gap that hinges on how far ABS-201 can travel in both hair loss and endometriosis.
Advancement of ABS-201 toward two proof of concept readouts in androgenetic alopecia and endometriosis over the next 24 months positions Absci to convert large underpenetrated markets into meaningful revenue growth and improved earnings power.
See why 13 investors see Absci as 25% undervalued.
Result: Fair Value of $13.78 (UNDERVALUED)
Still, Absci’s story hinges on early stage ABS-201 data and heavy spending against minimal revenue. As a result, weak trial results or rising cash burn could quickly challenge this undervalued narrative.
Find out about the key risks to this Absci narrative.
Next Steps
If the mixed mood around Absci has you on the fence, move quickly through the data, weigh the trade off between uncertainty and potential, then examine the 1 key reward and 3 important warning signs.
Looking for more investment ideas beyond Absci?
Do not stop your research with Absci. Broaden your watchlist with other clear, data backed opportunities that fit different risk levels and income goals.
- Target potential mispricing across quality companies by scanning a curated set of 27 high quality undervalued stocks built from consistent fundamentals and robust balance sheets.
- Prioritise resilience and sleep better at night by focusing on 31 resilient stocks with low risk scores that score well on financial strength and earnings stability.
- Get ahead of the crowd by tracking 19 high quality undiscovered gems that pair solid cash generation with cleaner balance sheets and lighter market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com